| L0 | L6m |
P (L0-6Â m)
| L12m |
P (L0–12 m)
| L+T0 | L+T6m |
P (L+T0–6 m)
| L+T12m |
P (L+T0–12 m)
|
---|
Weight | 61.48 | 63.98 |
0.004
| 61.03 |
0.007
a
| 58.65 | 61.18 |
0.023
| 65.10 |
0.001
|
SD | 0.16 | 0.36 |
0.120
| 0.01 |
0.911
| −0.38 | −0.13 |
0.016
| 0.01 |
0.001
|
BMI | 22.58 | 23.00 |
0.031
| 22.39 |
0.193
b
| 20.69 | 22.38 |
0.003
| 23.26 |
0.004
|
SD | 0.21 | 0.43 |
0.098
| 0.18 |
0.719
| −0.34 | 0.20 |
0.011
| 0.24 |
0.004
|
-
SD standard deviation in comparison with Flemish peers [27], L0 mean values before initiation of L, L6m mean values after 6 months of L; P(L0–6 m) P values of comparison of baseline parameters with values after 6 months of L, L12m mean values after 12 months of L, P(L0–12 m) P values of comparison of baseline parameters with values after 12 months of L, L+T0 mean values before initiation of L+T, L+T6m mean values after 6 months of L+T, P(L+T0–6 m) P values of comparison of baseline parameters with values after 6 months of L+T, L+T12m mean values after 12 months of L+T, P(L+T0–12 m) P values of comparison of baseline parameters with values after 12 months of L+T, L lynestrenol monotherapy, L+T lynestrenol and testosterone esters combination therapy
-
aAlthough mean weight of all patients seems to decrease, a significant increase in weight was noted when comparing weight at baseline with weight after 12Â months of L. This discrepancy is caused by exclusion of patients, who had not yet reached 12Â months of L at time of analysis
-
bBMI non-significantly increased after 12Â months of L, although mean BMI seems to decrease. This is due by the same phenomenon as described in a